What does it include in Humphrey Field Analyzer 3:
– One year Warranty (no additional cost)
– Patient response button
– Keyboard & Mouse
– Printer
– Table
– Manual on USB drive
– Professional packing
The ZEISS Humphrey Field Analyzer 3 with SITA Faster Testing: Revolutionizing Visual Field Tests
The Humphrey Field Analyzer 3 (HFA3) marks a significant advancement in the field of visual field testing, seamlessly integrating the features cherished in a Humphrey with expanded testing options and reduced patient test times. Let’s delve into the features and benefits of the ZEISS HFA3, highlighting how it optimizes results for both practitioners and their patients.
The ZEISS Humphrey HFA3 840 Field Analyzer revolutionizes visual field testing by combining the reliability of Humphrey technology with expanded testing options and reduced test times. Equipped with SITA Faster technology, it delivers precise and rapid results while streamlining workflow with features such as Liquid Trial Lens technology and automated eye alignment. A comprehensive solution for optimal patient management.
Expanding Testing Options with SITA Faster:
The ZEISS HFA3 introduces new testing options with SITA Faster 24-2 and 24-2C, enhancing patient management. These rapid tests are approximately 50% faster than standard SITA tests while maintaining equivalent reproducibility, thereby improving clinical workflow and patient satisfaction.
Progression Detection with GPA:
Guided Progression Analysis (GPA) stands as a pivotal feature of the ZEISS HFA3, aiding in determining the progression of visual field loss, its location, and rate, thereby facilitating tailored treatment adjustments. By identifying consecutive changes at each test point, the software provides precise analysis of disease progression.
Workflow Optimization:
The ZEISS HFA3 streamlines the testing process with Liquid Trial Lens technology, reducing setup time by automatically loading each patient’s refractive correction from previous exams. Automated eye alignment centers the patient’s eyes on the trial lens, ensuring swift setup and optimal results.
In a nutshell, the ZEISS HFA3 with SITA Faster Testing is a game-changer in visual field testing. It not only enhances the efficiency of clinical operations but also improves patient experience with faster tests and accurate results. This comprehensive solution empowers practitioners to make informed decisions and provides patients with superior care.
In-Depth Analysis and Data Visualization:
The new review software of the ZEISS HFA3 facilitates quick access to HFA reports in every examination room. Reports can be dynamically modified to include or exclude tests, reset baselines, and track subsequent tests in real-time. Data synchronization ensures seamless integration of tests from all connected HFA3 devices, providing a comprehensive patient history.
Additional Benefits:
SITA Faster 24-2: Offering approximately 30% faster testing compared to SITA Fast, SITA Faster 24-2 enhances efficiency without compromising result quality.
Interactive Results: Access ZEISS HFA3 results and the complete patient test history, allowing for on-the-fly adjustments to references for informed decision-making.
Integration with HFA-III: Synchronization of tests from HFA-III devices with the ZEISS HFA3 expands testing capacity, leveraging existing equipment to its fullest potential.
In summary, the ZEISS HFA3 represents a significant advancement in visual field testing, providing advanced features for optimal patient management. With its blend of speed, accuracy, and user-friendly interface, the HFA3 sets new standards in the industry, serving as an indispensable tool for visual healthcare practitioners
FEATURES
- SITA Faster technology for fast and accurate visual field tests
- Expanded testing options with SITA Faster 24-2 and 24-2C
- Guided Progression Analysis™ (GPA™) to detect the progression of visual field loss
- Liquid Trial Lens™ technology for quick and precise setup
- Automated eye alignment for optimal results
- Integration with HFA-IIi for data synchronization and expanded testing capacity
